Mean time to cancer-specific death of apparently clinically localized prostate cancer: Policy implications for threshold ages in prostate-specific antigen screening and ablative therapy

BJU International

Volumn 85, Issue 9, 2000, Pages 1063-1066

  Horan, A H ^a   McGehee, M ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Age limits; Mean time to death; PSA screening; Screening policy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; FOLLOW UP; HEALTH CARE POLICY; HUMAN; LIFE EXPECTANCY; MALE; MEDICAL RECORD; PALPATION; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL RATE; TIME OF DEATH;

AGE FACTORS; FOLLOW-UP STUDIES; HEALTH POLICY; HUMANS; LIFE EXPECTANCY; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; TIME FACTORS; UNITED STATES;

EID: 0034129268     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2000.00658.x     Document Type: Article

References (19)

1. IUCC. Prostate Cancer. A Scries of Workshops on the Biology of Human Cancer. Report #9. Geneva: International Union Against Cancer, 1979:235
2. Berges RR, Vukanovic J, Epstein JI et al. Implications of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-80
3. Stenman U, Oesterling JE. Impact of tumor doubling time and age-based reference value for PSA on prostate cancer screening outcome. J Urol 1995; 153: 505A
4. Slezak J, Iocca AJ, Blute ML, Zincke H. Do results of radical prostatectomy for PSA detected cancer (T1c) support PSA screening J Urol 1999; 161: 387
5. Wilt T, Brawer MK, Wheeler T, Weiss DG. The prostate cancer intervention versus observation trial (PIVOT): preliminary baseline results. Abstract, Western Section AUA, Hawaii October 25-30 1998
6. Vaugh ED, Schlegel PN, Perlmutter AP. Clinician's manual on prostate-specific antigen. Current Medicine. Geneva: International Union Against Cancer, 1998: 37
7. National Center Health Statistics. Vital Statistics of the United States, 1994, 2. Life Tables, Section 6, Hyattsville MD: NCHS 1994
8. Kiely T. CDC Holds International Conference on Prostate Cancer. Health Policy Brief. AUA. Baltimore MD, October 6 1995
9. Lowe B, Listrom MB. Incidental carcinoma of the prostate: an analysis of the predictors of progression. J Urol 1988; 140: 1340-4
10. Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN + adenocarcinoma of the prostate treated with radical prostatectomy and early androgen ablation. J Urol 1998; 159: 357-64
11. Guttman C. Study quantifies benefits of conservative management in Pea. JAMA 1998; 280: 975-80
12. Hugosson J, Aus G, Bergdahl C, Bergdahl S. Prostate cancer mortality in patients surviving more than 10 years after diagnosis. J Urol 1995; 154: 2115-7
13. Pound CR, Partin AW, Walsh PC. The natural history of progression to metastases and death due to prostate cancer in men with PSA recurrence following radical prostatectomy. Abstract 1283. AUA News November/December, 1998: 31
14. Middleton RG, Thompson IM, Austenfeld MS et al. Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate Cancer. J Urol 1995; 154: 2144-8
15. Moul JW. The changing face of prostate cancer in the late 1990s. New Developments in Prostate Cancer Treatment Glenview IL: Physicians and Scientists Publishing, 1998: 80
16. Horan AH. Localized therapy for prostate cancer: private-versus public-sector practice. Federal Practitioner 1999: April: 30
17. Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998; 160: 2418-24
18. The American Urological Association Prostate Cancer Clinical Guidelines Panel. Technical Supplement and appendix C. Baltimore MD: AUA, 1995:22
19. Hirano D, Werahera P, Crawford ED, Lucia MS, DeAntoni EP, Miller GJ. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor, grade, tumor doubling time, and life expectancy. J Urol 1998; 159: 1265-9